Coherus shrinks headcount 30% to narrow focus of cancer combo
Coherus Oncology is once again laying off 30% of its workforce as the biopharma narrows the focus of its investigational combo treatment to esophageal cancer.
Coherus Oncology
NASDAQ: CHRS $0.64 USD
Commercial-stage oncology company whose lead product LOQTORZI (toripalimab-tpzi) is an approved next-generation anti-PD-1 antibody, with a clinical pipeline of immuno-oncology combinations targeting CCR8 and IL-27 for liver, head and neck, prostate and colorectal cancers.
Company Info
Sector:Biotechnology — Oncology
Headquarters:Redwood City, California, USA
Founded:2010
Website:www.coherus.com/
Clinical Development Pipeline
LOQTORZI (toripalimab-tpzi)
Target: PD-1Tagmokitug
Target: CCR8Casdozokitug
Target: IL-27Recent News
Leadership Team
Dennis M. Lanfear
President, Chief Executive Officer & Chairman